SAI PARENTERALS LIMITED

During the earnings conference call held on August 12, 2026, management reported that Sai Parenterals Limited achieved consolidated total revenue of Rs. 182 crores for Q1 FY '27, a decrease from Rs. 201 crores in Q4 FY '26. Gross profit was Rs. 76 crores with a gross margin of 41.8%, and EBITDA was Rs. 27 crores at a margin of 14.9%. Management noted that the first quarter represented approximately 24% of their full-year revenue goal of Rs. 750 crores. They discussed strategic developments, including a proposed variation in IPO fund usage to acquire stakes in two pharmaceutical assets, which management stated would enhance capacity and capabilities. The company also provided updates on their Australian facility, which is on schedule for completion in January 2027. Management reiterated their revenue guidance of Rs. 750 crores for FY '27 with an EBITDA margin of around 17%.

Management provided a detailed overview of financial performance and strategic initiatives without strong emphasis on growth or challenges.